These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30849317)

  • 1. Vedolizumab Does Not Impair Sperm DNA Integrity in Men With Inflammatory Bowel Disease.
    Grosen A; Bungum M; Hvas CL; Julsgaard M; Cordelli E; Kelsen J
    Gastroenterology; 2019 Jun; 156(8):2342-2344. PubMed ID: 30849317
    [No Abstract]   [Full Text] [Related]  

  • 2. Methotrexate Reduces DNA Integrity in Sperm From Men With Inflammatory Bowel Disease.
    Ley D; Jones J; Parrish J; Salih S; Caldera F; Tirado E; Leader B; Saha S
    Gastroenterology; 2018 Jun; 154(8):2064-2067.e3. PubMed ID: 29481778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.
    Julsgaard M; Kjeldsen J; Bibby BM; Brock B; Baumgart DC
    Gastroenterology; 2018 Feb; 154(3):752-754.e1. PubMed ID: 28988916
    [No Abstract]   [Full Text] [Related]  

  • 4. Arthritis occurrence or reactivation under Vedolizumab treatment for inflammatory bowel disease. A four cases report.
    Wendling D; Sondag M; Verhoeven F; Vuitton L; Koch S; Prati C
    Joint Bone Spine; 2018 Mar; 85(2):255-256. PubMed ID: 28238881
    [No Abstract]   [Full Text] [Related]  

  • 5. Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.
    Asscher VER; Biemans VBC; Pierik MJ; Dijkstra G; Löwenberg M; van der Marel S; de Boer NKH; Bodelier AGL; Jansen JM; West RL; Haans JJL; van Dop WA; Weersma RK; Hoentjen F; Maljaars PWJ;
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1366-1376. PubMed ID: 32901983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
    Amiot A; Grimaud JC; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Bouhnik Y; ;
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1593-1601.e2. PubMed ID: 26917043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vedolizumab (Entyvio) for inflammatory bowel disease.
    Med Lett Drugs Ther; 2014 Sep; 56(1451):86-8. PubMed ID: 25211302
    [No Abstract]   [Full Text] [Related]  

  • 8. Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series.
    Lim TY; Pavlidis P; Gulati S; Pirani T; Samaan M; Chung-Faye G; Dubois P; Irving P; Heneghan M; Hayee B
    Inflamm Bowel Dis; 2016 Oct; 22(10):E39-40. PubMed ID: 27556837
    [No Abstract]   [Full Text] [Related]  

  • 9. Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease.
    Navaneethan U; Edminister T; Zhu X; Kommaraju K; Glover S
    Inflamm Bowel Dis; 2017 Apr; 23(4):E17. PubMed ID: 28296827
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
    Dig Dis Sci; 2018 Apr; 63(4):825-833. PubMed ID: 29484571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab.
    Hussar DA; Nguyen A
    J Am Pharm Assoc (2003); 2014; 54(6):658-62. PubMed ID: 25379985
    [No Abstract]   [Full Text] [Related]  

  • 12. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
    Ledder O; Assa A; Levine A; Escher JC; de Ridder L; Ruemmele F; Shah N; Shaoul R; Wolters VM; Rodrigues A; Uhlig HH; Posovszky C; Kolho KL; Jakobsen C; Cohen S; Shouval DS; de Meij T; Martin-de-Carpi J; Richmond L; Bronsky J; Friedman M; Turner D
    J Crohns Colitis; 2017 Oct; 11(10):1230-1237. PubMed ID: 28605483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study.
    Zwicker S; Lira-Junior R; Höög C; Almer S; Boström EA
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
    Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
    Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
    Yacoub W; Williet N; Pouillon L; Di-Bernado T; De Carvalho Bittencourt M; Nancey S; Lopez A; Paul S; Zallot C; Roblin X; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2018 Apr; 47(7):906-912. PubMed ID: 29384209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
    Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
    J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation.
    Wright AP; Fontana RJ; Stidham RW
    Liver Transpl; 2017 Jul; 23(7):968-971. PubMed ID: 28296011
    [No Abstract]   [Full Text] [Related]  

  • 18. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease.
    Lightner AL; Tse CS; Potter DD; Moir C
    J Pediatr Surg; 2018 Sep; 53(9):1706-1709. PubMed ID: 29111083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter to editor: New onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease.
    Tamanini S; Fredi M; Crisafulli F; Lazzaroni MG; Tincani A; Franceschini F
    Clin Rheumatol; 2019 Feb; 38(2):609-610. PubMed ID: 30397839
    [No Abstract]   [Full Text] [Related]  

  • 20. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
    Smith MA; Mohammad RA
    Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.